Cancer du rectum avec métastases synchrones non résécables: les arguments du choix thérapeutique
Jean-Baptiste Bachet , Emmanuel Mitry , Stéphane Benoist , Jean-Nicolas Vaillant
Cancéro digest 1 ( 2) 126 -133
2009
Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastatic colorectal cancer.
Gilles Manceau , Jean-Baptiste Bachet , Benoist Chibaudel , Francois Liebaert
Journal of Clinical Oncology 31 3562 -3562
1
2013
Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial
Christophe Tournigand , Thierry André , Franck Bonnetain , Benoist Chibaudel
Journal of Clinical Oncology 30 ( 27) 3353 -3360
237
2012
Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.
Isabelle Trouilloud , Olivier Dubreuil , Tarek Boussaha , Céline Lepère
Clinics and Research in Hepatology and Gastroenterology 35 ( 5) 364 -374
15
2011
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Hampig Kourie , Edouard Auclin , Antonio Sa Cunha , Sebastien Gaujoux
Clinics and Research in Hepatology and Gastroenterology 43 ( 6) 663 -668
5
2019
Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: A multicenter prospective AGEO study.
Lola-Jade Palmieri , Olivier Dubreuil , Jean-Baptiste Bachet , Isabelle Trouilloud
Clinics and Research in Hepatology and Gastroenterology 45 ( 1) 101431
2021
Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma.
Paul McLellan , Julie Henriques , Feryel Ksontini , Solène Doat
Clinics and Research in Hepatology and Gastroenterology 45 ( 3) 101541
1
2021
Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
Renato M. Lupinacci , Jean-Baptiste Bachet , Thierry André , Alex Duval
Surgical Oncology-oxford 28 121 -127
5
2019
Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases.
Gilles Manceau , Antoine Brouquet , Jean-Baptiste Bachet , Christophe Penna
Surgery 154 ( 3) 528 -535
15
2013
Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.
Jean-Baptiste Bachet , Fabien Gay , Raphaël Maréchal , Marie-Pierre Galais
Pancreas 44 ( 7) 1141 -1147
36
2015
Feasibility of Immunohistochemistry on Endoscopic Ultrasound Fine-Needle Aspiration Samples for Evaluating Predictive Biomarkers in Pancreatic Cancer Management
Francesco Puleo , Pieter Demetter , Pierre Eisendrath , Raphaël Maréchal
Pancreas 45 ( 9) e50 -e52
1
2016
Prognostic value of high c-Met expression in patients with poor prognosis pancreatic adenocarcinoma (PAC) following surgical resection: comparison of three c-Met scoring methods and exploration of underlying mechanisms of c-Met overexpression
Cindy Neuzillet , Annemilaï Tijeras-Raballand , Jérôme Raffenne , Armand D.E. Gramont
Pancreatology 15 ( 3)
2015
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Astrid Lièvre , Emmanuelle Samalin , Emmanuel Mitry , Eric Assenat
BMC Cancer 9 ( 1) 347 -347
40
2009
Abstract A61: CAF-derived ANXA6+-exosomes support pancreatic cancer aggressiveness and serve as a circulating biomarker
Julie Leca , Sebastien Martinez , Sophie Lac , Jeremy Nigri
Cancer Research 76
2016
BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
Leo Mas , Jean-Baptiste Bachet , Valerie Taly , Olivier Bouché
Cancers 11 ( 7) 998
8
2019
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
Jerome Raffenne , Remy Nicolle , Francesco Puleo , Delphine Le Corre
Cancers 11 ( 11) 1808
12
2019
From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer
Aimery de Gramont , Armand de Gramont , Benoist Chibaudel , Jean-Baptiste Bachet
Seminars in Oncology 38 ( 4) 521 -532
32
2011
Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer.
Lola-Jade Palmieri , Amina Fihri , Solène Doat , Olivier Dubreuil
European Radiology 29 ( 7) 3871 -3880
5
2019
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Jean-Baptiste Bachet , Pascal Hammel , Jérôme Desramé , Aurélia Meurisse
The Lancet Gastroenterology & Hepatology 2 ( 5) 337 -346
18
2017
Abstract A107: c-Met overexpression as an independent prognostic biomarker and therapeutic target in patients with poor prognostic pancreatic adenocarcinoma following surgical resection
Cindy Neuzillet , Jérôme Cros , Annemilaï Tijeras-Raballand , Armand De Gramont
Cancer Research 75
2015